Anti-PD-1 (Programmed Death-1) antibody and application thereof

Abstract

The invention provides an antibody specifically combined with PD-1 (Programmed Death-1) with high affinity, and also provides a nucleic acid molecule for coding the antibody, an expression vector and a host cell for expressing the antibody, and a production method of the antibody. In addition, the invention also provides an immune conjugate and a medicinal composition containing the antibody, and application of the antibody to the preparation of a medicine for treating multiple diseases (including a cancer, an infectious disease and an inflammatory disease).

Description

technical field [0001] The present invention belongs to the field of therapeutic monoclonal antibodies, more specifically, the present invention relates to an antibody against programmed death receptor (PD-1); , inflammatory diseases). Background technique [0002] Programmed Death-1 (PD-1), a member of the CD28 family, is an immunosuppressive receptor expressed on the surface of activated T cells and B cells (Yao Zhu et al., Nat Rev Drug Discov, 2013; 12(2):130-146), originally obtained by subtractive hybridization in apoptotic T-cell hybridomas. PD-1 is mainly expressed in CD 4+ T cells, CD 8+ The surface of T cells, NK-T cells, B cells and activated monocytes is mainly induced by T cell receptor (TCR) or B cell receptor (BCR) signaling, and TNFα can enhance the expression of PD-1 on the surface of these cells (Francisco LM et al., Immunol Rev, 2010; 236:219-242). The PD-1 molecule consists of an extracellular domain, a transmembrane domain and an intracellular domain...

AI Technical Summary

Problems solved by technology

Although a variety of monoclonal antibodies against immune checkpoints such as PD-1, PD-L1 and CTLA4 have been used clinically, the response rate of these antibodies as a single drug is still low, with an average of only 15-20%

Images